| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BIIB | Common Stock | Options Exercise | $0 | +1.79K | +19.31% | $0.00 | 11.1K | Feb 17, 2023 | Direct | |
| transaction | BIIB | Common Stock | Tax liability | -$241K | -867 | -8.54% | $278.38 | 9.28K | Feb 17, 2023 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BIIB | Restricted Stock Unit | Options Exercise | $0 | -1.79K | -26.48% | $0.00 | 4.98K | Feb 17, 2023 | Common Stock | 1.79K | $0.00 | Direct | F1 |
| transaction | BIIB | Restricted Stock Unit | Other | $0 | -1.59K | -31.95% | $0.00 | 3.39K | Feb 17, 2023 | Common Stock | 1.59K | $0.00 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| F2 | This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. |